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Abstract
Objective: Antisnake venom (ASV) is a specific antidote for the management of snake bite 
envenomations. This study profiled the treatment and outcome of adult snake bite victims managed using 
low dose antisnake venom. 
Methods: This was a 5-year retrospective study that involved all adult patients who presented in 
University of Benin Teaching Hospital, Benin City, Nigeria, with a history of snake bite. Information 
obtained were demographic characteristics, clinical features, and administered treatment per established. 
All patients with a diagnosis of snake bite envenomation were administered ASV. 
Results: Sixty patients were seen during the study period, 35(58.3%) males, 25(41.7%) females with a 
mean age was 34.7±13.3. The mean time from bite to presentation was 14.67±14.05 hours with range of 1-
48 hours. Twenty patients (33.3%) had snake bite envenomations, of these eleven (57.9%) were managed 
and discharged after administration of 30 to 40 mls of polyvalent ASV. The mean dose of PASV used was 
3.9 ± 2.0 vials. The most encountered clinical indication for ASV administration was progressive painful 
swelling. No death was recorded throughout this period studied. 
Conclusion: Adoption of the low dose regimen in the management of snake bite envenomations may be as 
effective as the traditional high dose regimen. 
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Le traitement des morsures de serpents chez les adultes, par 
l'administration d'une faible dose d'anti-venin de serpent. Une étude 
rétrospective étalée sur 5 ans, dans un centre hospitalier universitaire à 
Benin City au Nigéria. 
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Résumé
Objectif: L'anti-venin du serpent (AVS) est un antidote destiné à traiter les envenimations causées par les 
morsures de serpents. Cette étude s'intéresse au traitement donné aux adultes victimes de morsure de 
serpent et à leur état de santé, après avoir reçu une faible dose d'anti-venin de serpent. 
Méthodes: tous les patients adultes qui avaient été reçus aux services des urgences du CHU de Benin City 
au Nigéria, suite à une morsure de serpent, ont pris part à cette étude. Les informations récoltées l'ont été 
sur les données démographiques, les manifestations cliniques et les traitements donnés selon un protocole 
établi. Cette étude rétrospective et descriptive fut menée entre janvier 2013 et octobre 2017. L'ensemble 
des patients à qui on a diagnostiqué une envenimation par morsure de reptile a reçu un anti-venin de 
serpent (AVS). 
Résultats : soixante patients ont été examinés pendant l'étude, 35 hommes (58,3%) et 25 femmes 
(41,7%). La moyenne d'âge se situait à 34,7 ans  (+ ou – 13,3), avec des âges compris entre 18 et 83 ans. Le 
délai moyen observé entre la morsure et la présentation au CHU s'élevait à 14,67 heures (+ ou – 14,05 
heures), avec des variables de 1 heure à 48 heures.  Vingt patients (33%) furent infectés par une morsure de 
serpent, onze d'entre eux (57,9%) ont été traités et libérés après l'administration de 30 à 40 millilitres 
d'anti-venin de serpent polyvalent (AVSP). La dose moyenne administrée d'anti-venin de serpent 
polyvalent (par ampoule) s'est élevée à 3,9 (+ ou – 2.0). La justification médicale la plus avancée pour 
répondre de l'injection de l'anti-venin de serpent polyvalent résidait dans l'apparition d'un gonflement 
progressif douloureux. Aucun décès n'a été enregistré au cours de l'étude. 
Conclusion : cette étude a montré qu'opter pour un traitement à faible dose après une morsure infectée de 
serpent pouvait être aussi efficace qu'une administration usuelle à forte dose. A terme, elle peut encourager 
une utilisation judicieuse de l'anti-venin de serpent. 
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INTRODUCTION
Envenomation following Snake bite is a 
neglected clinical problem especially in the 
tropics (1). Accurate disease burden data is 
lacking, and documented estimates underscore 
the scale of the problem. However, a study in 
West Africa reported an annual incidence of 
54/100,000 persons per year (PPY) and a 
mortality of 1.35/100,000 persons per year (PPY) 
annually (2). 
There are many species of snakes 
worldwide but only 10-15% are poisonous. 
Venomous snakes are widely distributed in 
0 0almost every country between 50 N and 50  S in 
0 0the western hemisphere and 65  N and 50  S in the 
 
Eastern hemisphere (3). This includes Africa, 
Asia, Latin America, and the Oceanic countries. 
In Africa, they belong to four main families - 
viperidae, elapidae, hydrophidae ,  and 
colubridae. However in Nigeria, the most 
common poisonous snakes are the elapids and the 
viperids (4). Antisnake venom (ASV) is the only 
specific antidote for the management of snake 
bite envenomations. The conventional 
administration of ASV is based on the Blaylock 
algorithm (5) which follows a syndromic 
approach and puts into cognizance the clinical 
presentation of the patient, the severity of the bite, 
and the dose of the antivenom administered. This 
approach to snake bite management requires that 
victims receive polyvalent ASV at initial doses of 
50mls for mild envenomations, 100mls for 
moderate envenomations, and 150mls for severe 
envenomations, despite the challenges of 
availability, accessibility and cost. This has led to 
a number of studies utilizing low dose ASV 
regimen (6-8), as against the conventional high 
doses with comparable efficacy in patient 
outcome.  
The burden of snake bite in Nigeria is 
highest in the northern regions especially the 
Benue valley where incidence as high as 467 per 
100,000 PPY has been reported (9). It is therefore 
not surprising that most of the research studies on 
snake bite in Nigeria have come from this region. 
This retrospective study has therefore been 
undertaken to profile the treatment and the 
outcome of adult snake bite victims managed in 
our centre using a low dose treatment regimen.  
MATERIALS AND METHODS
This study was carried out in the 
University of Benin Teaching Hospital (UBTH), 
Benin City, Edo State, South South, Nigeria. It is 
a federal government tertiary hospital with a 850 
bed space capacity, and a referral centre for Edo 
State and the adjoining states. This study was 
conducted between January 2013 and October 
2017. It is a retrospective study. All adult patients 
with a history of snake bites who presented to the 
adult Medical Emergency Department were 
included in this study. Data were extracted from 
case notes and entered into a predesigned 
proforma data sheet. Information extracted 
included patients demographics, place of bite, 
time of bite, site of bite, clinical presentation, 
t r e a t m e n t  g i v e n  b e f o r e  a n d  d u r i n g  
hospitalization, doses of antisnake venom 
administered, occurrence of adverse drug 
reaction, length of hospital stay and outcome of 
treatment.
Treatment Protocol 
All patients with a diagnosis of snake bite 
were categorized into 2 groups- those with 
envenomation and those who had unconvincing 
features of envenomation. The latter group were 
observed for at least 24 hours thereafter are either 
discharged home or admitted if signs of 
envenomation become evident. Patients with 
features of envenomation were administered 
antisnake venom (ASV) a liquid, polyvalent, 
Enzyme refined Equine immunoglobulins ( 
PASV), manufactured by Premium Serums and 
Vaccines PVT LTD, Maharashtra, India. The 
polyvalent ASV consists of hyperimmune horse 
serum against four common snakes- cobra, 
common krait, Russell's viper and saw- scale 
viper. , Patients were administered low doses of 
the PASV in line with the treatment regimen 
adopted (10). Each patient with envenomation 
had an initial dose of 20mls of PASV diluted in 
100mls of 5% glucose solution given 
intravenously over one hour, after an intradermal 
test dose. Thereafter the patient is reassessed for 
progression of clinical features. If no changes a 
further 10mls of PASV in 100mls glucose 5% 
solution is administered over four hours. This is 
repeated until there is improvement of clinical 
condition, then 10mls of PASV in 500mls of 
glucose 5% solution is administered for the next 
24 hours. Patients were closely monitored for 
allergic reactions and managed accordingly with 
epinephrine, promethazine and hydrocortisone. 
All patients had crude clotting time done and had 
tetanus toxoid administered. Other medications 
administered included tramadol and prophylactic 
antibiotics.
Ethical approval was obtained from the 
University Teaching Hospital Ethics and 
Research Committee. 
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Statistical Analysis
All data from the proformal data spread sheet 
were coded accordingly and entered for statistical 
analysis using SPSS software version 21. Results 
were expressed as means (± SD) and percentages 
where necessary. Descriptive statistics was used 
to summarize baseline values and demography. 
Chi square test was used to compare proportions. 
A P-value of < 0.05 was considered as 
statistically significant.
RESULTS   
A total of 60 patients were seen during 
the study period, of these 35 (58.3%) were males 
while 25 (41.7%) were females. The overall mean 
age was 34.72 ± 13.3, with an age range of 18-83 
years. Although more males were recorded in this 
study however differences in gender were not 
significant. The age group 18-40 years 
constituted 73.3% of the victims, Table 1. 
Most of the patients (95%) had bites to 
the lower limbs, although there was also a report 
of upper limb and ocular envenomation. The 
mean time from bite to presentation was 
14.67±14.05 hours (median time 11.5hours, 
range (1-48) hours. The most encountered 
clinical presentation was localized pain (45%) at 
the site of bite, followed by progressive pain and 
swelling (13.3%). Other manifestations were 
prolonged clotting time (5%), local bleeding 
(3.3%), hypotension (3.3%) and constitutional 
symptoms (1.7%). Compartment syndrome was 
diagnosed clinically in only one patient who was 
bitten by a puff adder and subsequently had 
fasciotomy and removal of two gangrenous 
digital fingers. There were no neurological 
manifestations. (Table 2). Most bites were 
recorded in April and September. (Figure 1).
The management and outcome of snake 
bite is presented in Table 3. A total of twenty 
patients (33.3%) received Polyvalent antisnake 
venom (PASV),.Of these, eleven(57.9%) were 
managed and discharged after administration of 
30 to 40 mls of  PASV(a vial equivalent to 10 
mls). The mean dose (vials) of PASV used was 
3.9 ± 2.0 STD.  Those who had only a single dose 
of antisnake venom could not purchase additional 
vials due to financial constraints. The only patient 
that had 8 vials of PASV presented with 
compartment syndrome. All patients with snake 
bite envenomation also received prophylactic 
antibiotics mostly ceftriaxone and metronidazole 
combination (32.6%). Tramadol was the most 
prescribed analgesic (43.3%). Very few (8.3%) of 
the snake bite victims developed allergic 
reactions to the PASV and were managed with a 
combination of hydrocortisone and promethazine  
Tetanus toxoid was administered to all patients 
with snake bite. No death was recorded 
throughout this period of study. 
DISCUSSION
This study highlighted and brought to 
fore some perspective of clinical presentation and 
care of patients presenting with snake bites. 
Studies of snake bite that are hospital based are 3 
to 5 times lower in prevalence compared to 
household or community based studies (11). A 
previous study showed that only 8.5% of snake 
bite victims present to hospital facilities in 
Nigeria (12), as most victims patronize 
traditional healers.  This may be a reflection of 
the number of cases that reported in our facility 
during this period of study. More males and 
younger adults were most affected. This group is 
known to be more adventurous and more likely to 
engage in activities that puts them at a higher risk 
of snake bite such as farming, bush clearing and 
burning, and keeping late nights.  Most victims 
reported in the month of April. This is the 
beginning of the raining season which coincides 
with the snake breeding periods and an increase 
in agricultural activities, thus contacts between 
snakes and humans are relatively common (13). 
Another peak period of snake bite is the dry 
season when farm produce are usually harvested 
and there is increased bush burning. Snakes being 
ectothermic, come out of hiding during this 
period to find heat so as to regulate their body 
temperature. They are also said to be more active 
when warmer.  
Sixty seven percent of victims were not 
administered the antisnake venom since there 
were no clinical features suggesting snake bite 
envenomations after 24 hours. Definite snake 
bites that result in negligible or no symptoms may 
have been 'dry bites' inflicted by venomous 
snakes or bites by non- venomous snakes. It is 
important to note that a proportion of bites do not 
result in the injection of sufficient venom to cause 
clinical effects. The amount and potency of the 
venom usually depends on the specie type, size of 
the snake, mechanical efficiency of the bite, and 
[14]the aggravating factor.  Victims of snake bite 
usually know they have been bitten except those 
who experience painless nocturnal bits by Kraits 
while asleep. In this study the average dose of 
PASV administered in vials was 3.9 ± 2.0. This 
was less when compared with other low dose 
studies (6, 15). The most common indication for 
use of polyvalent antisnake venom (PASV) in this 
study was progressive painful swelling. 
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Vasculotoxic snake envenomations are usually 
associated with local tissue swelling within 2-4 
hours and could extend rapidly to reach its peak in 
2nd to 3rd day. Blistering and tissue necrosis 
becomes obvious within the first day of bite, 
while coagulopathy and bleeding may develop 
within a few hours (14,16). The only patient who 
presented with compartment syndrome was 
reported to be bitten by the puff adder. Depending 
on the size of the fangs, venom is injected either 
subcutaneously or intramuscularly. The 
incidence of clinical compartment syndrome in 
snake bite is low because most snake fangs 
penetrate the subcutaneous tissue rather than the 
muscle compartment (17).
The relative delay in the presentation of 
these patients were due mostly to self 
medications and patronage of traditional healers. 
Traditional medical practitioners make use of 
concoctions which are administered either orally 
or applied topically. In Nigeria, certain herbs 
such as Aristollchia albida,Guiera senegalensis, 
were found to act on snake venoms in 
experimental animals but findings were not 
conclusive (12).  Prior visits for traditional 
treatment should be highly discouraged because 
it delays presentation, may distort the clinical 
picture, with the increased risk of other 
complications such as bleeding, infection and 
gangrene.
We also discovered that 16% of the 
patients could only afford one vial of the PASV 
and were unable to purchase more due to their 
high cost (a vial cost 45 to 46 US dollars). . Again, 
at other occasions, the unavailability of the PASV 
in the hospital puts the burden on the care givers 
to scout for these medicines in pharmacy outlets, 
at the risk of purchasing substandard products. 
Hence the victims are only given supportive 
treatment until the antivenoms are made 
available.  Antisnake venom is the only effective 
specific antidote for snake bite envenomation 
(14). Polyvalent antisnake venom are raised 
against the venoms of the most medically 
important snakes species in a particular 
geographical area. If given early it reverses both 
the local and systemic presentations. However 
their cost, availability and accessibility, still 
remains a challenge especially in areas of high 
demand (18). Available studies have shown that 
low doses of PASV are as good or even better 
(lesser complications) when compared with 
 
conventional high doses (19,20). However the 
recent situation of unavailability of PASV as was 
recently the case in Gombe and Plateau states, of 
Nigeria, which led to the death of 91 victims 
within a period of three weeks reaffirms the need 
for judicious use of these essential medicines 
(21). 
The incidence of allergic reactions was 
low among these patients administered the 
antisnake venom. This may not be associated 
with the doses of the antivenom since the 
reactions are often immunological. This is 
because the antivenom is hyperimmune globulin 
extracted from the plasma of the animal that has 
been immunised with the appropriate venom. The 
oral flora of snakes is heavily colonized by 
bacteria which predisposes these victims to early 
bacterial infection with the possibility of 
developing tetanus infection. As such, in our 
centre, all snake bite victims are given tetanus 
toxoid and those with envenomations 
administered prophylactic antibiotics. However 
some centers encourage the use of antibiotics 
only in the presence of necrosis or iatrogenic 
interference of bite site. Although no mortality 
was recorded throughout this study period, the 
outcome of patients who discontinued treatment 
and discharged themselves due to financial 
constraints was not ascertained. 
CONCLUSION
In conclusion, the use of low dose 
antisnake venom in the snake bite victims in this 
study was found to be effective in ameliorating 
the features of envenomation. Cost consideration 
of the PASV is an important factor in the 
treatment of snake bite envenomation. There is 
need for government and funding agencies to 
give more attention to snake bite envenoming in 
other to ensure that antisnake venom are highly 
subsidized or are given to these victims at no cost. 
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Table 1: Age and Sex characteristics of patients seen  
with snake bite at the adult medical emergency of UBTH. 
 
Age group (Years)                        Gender 
 Male (%) Female (%)  
18-40 23(52.3) 21(47.7) 
41-65 11(73.3) 4(26.7) 
65-99 1(100) 0 





Table 2: Site of bite and clinical presentations of snake bite  
victims in the adult medical emergency department. 
 
Site of bite Number of 
victims (n) 
Percentage (%) 
Foot  57 95.0 
Hand  1 1.7 
Thigh  1 1.7 




Local Pain 27 45 
Local pain and swelling 8 13.3 
Local bleeding 2 3.3 
Hypotension 2 3.3 
Prolonged clotting time 3 5 
Constitutional symptoms 1 1.7 






Figure 1: Monthly distribution of presentation of snake bite victims to the adult  
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Table 3: The management and outcome of patients with snake bite 
 
Admission status Number of victims(n) Percentage (%) 
Admitted 20 33.3 
Not admitted 40 66.7 
Administration of PASV   
Yes 19 95 
No 1 5 
Antibiotic use   
Yes 19 32.8 
No 41 67.2 
Tetanus toxoid use   
Yes  60 100 
No 0  
Analgesics   
Paracetamol 2 3.3 
Tramadol  26 43.3 
Pentazocine 2 3.3 
Diclofenac  1 1.7 
Steroids   
Hydrocortisone  5 8.3 
Antihistamine   
Promethazine 5 8.3 
Blood transfusion   
Yes 1(6 units of blood) 1.7 
Other medicines   
Amitriptyline  1 1.7 
Omeprazole  1 1.7 
Outcome   
Discharged 50 83.3 
Discharged against medical advice 
(DAMA) 
10 16.7 
Death 0 0 
Doses of PASV administered 
(mls) 
Number of Patients (n)  
10 3 15.8 
20 1 5.3 
30 3 15.8 
40 8 42.1 
60 2 10.5 
80 2 10.5 
Antibiotics administered   
Ceftriazone  14 32.6 
Metronidazole  16 37.2 
Levofloxacin  6 14.0 
Ciprofloxacin  3 7.0 
Cefuroxime  2 5.0 
Ofloxacin  1 2.3 
Coamoxiclav  1 2.3 
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